Milestone Pharmaceuticals Inc. (MIST)

USD 1.7

(-6.59%)

Market Cap (In USD)

90.65 Million

Revenue (In USD)

1 Million

Net Income (In USD)

-59.68 Million

Avg. Volume

113.6 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.12-2.93
PE
-
EPS
-
Beta Value
1.729
ISIN
CA59935V1076
CUSIP
59935V107
CIK
1408443
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Joseph G. Oliveto M.B.A.
Employee Count
-
Website
https://www.milestonepharma.com
Ipo Date
2019-05-09
Details
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.